Skip to main content
Andrea Eleazar on Muck Rack

Andrea Eleazar

(She/Her)
New Jersey, New York, Philadelphia
As seen in: American Journal of Managed Care, ONCOLOGY journal, CURE Magazine, OncLive, Targeted Oncology, Oncology Nursing News
Covers:  Health, Science, Food & Drink

Get in touch with Andrea

Contact Andrea, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Andrea Eleazar’s Journalist Portfolio

Press Release: To Reap Good Yields: A Grain of Genetic Insight into Amaranth

Press Release: To Reap Good Yields: A Grain of Genetic Insight into Amaranth

In a study published in the August issue of the Journal of Young Investigators , Abiola Samson Olaniyi of Osu…

View article →
Press Release: University Students Paying the Psychological Price of Quarantine

Press Release: University Students Paying the Psychological Price of Quarantine

Al Refaei, Shewaikani, and colleagues from the University of Jordan, University of Baghdad, and University of…

View article →
A Pandemic Paradox: Health Disparities of U.S. Filipino Frontliners From Colonization to COVID-19

A Pandemic Paradox: Health Disparities of U.S. Filipino Frontliners From Colonization to COVID-19

This past October marked the 30th annual Filipino American History Month (FAHM), recognizing the contribution…

View article →

Articles

Izalontamab Brengitecan Improves OS/PFS in Advanced/Metastatic TNBC

|
By Sabrina Serani Verified, Andrea Eleazar, Russ Conroy
| ONCOLOGY journal Verified
Findings from the phase 3 PANKU-Breast02 trial (NCT06382142) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed significant improvements in progression-free survival (PFS) and overall survival (OS) with izalontamab brengitecan (iza-bren), an investigational bispecific antibody-drug conjugate (ADC), over chemotherapy among those with previously treated unresected locally advanced or metastatic triple-negative breast cancer (TNBC).
Open in Who Shared View Duplicates (2) Issue with article?

Ipilimumab Plus Nivolumab-Relatlimab Triplet Yields High MPR in Resectable Melanoma

|
By Ariana Pelosci Verified, Tim Cortese, Andrea Eleazar
| ONCOLOGY journal Verified
Potent and durable tumor responses were noted with neoadjuvant ipilimumab (Yervoy) plus nivolumab and relatlimab-rmbw (Opdulag) in patients with macroscopic resectable clinical stage IIIB, IIIC, IIID melanoma, according to results from the phase 2 NeoINR trial (NCT06295159) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Among the 19 patients who underwent surgery with pathologic response assessment, the NeoINR regimen achieved a pathological complete...
Open in Who Shared Issue with article?

Pembrolizumab/Vaccine Combo Improves RFS in High-Risk Resected Melanoma

|
By Andrea Eleazar, Sabrina Serani Verified, Jason Broderick Verified
| ONCOLOGY journal Verified
Meaningful improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were observed with a mRNA-based cancer vaccine, intismeran autogene, plus pembrolizumab (Keytruda) among patients with high-risk resected melanoma, according to a presentation at the 2026 American Society of Clinical Oncology Annual Meeting (ASCO) on 5-year follow-up data from the phase 2 KEYNOTE-942 trial (NCT03897881).1 With a median planned follow-up of 60.3 months (range, 50.5-76.4...
Open in Who Shared View Duplicates (2) Issue with article?
See all 53 licensed articles (1,014 Total)